Established in 2018, Omni-stat Medical develops temporary topical hemostats for controlling bleeding in hospital and emergency-care settings. Its OMNI-STAT and CELOX products use proprietary chitosan granule technology, developed for wounds ranging from minor bleeding to severe arterial injuries and shown to work in the presence of common anticoagulants. The New York-based company is a subsidiary of Medtrade Products Limited and provides product training alongside its clinical solutions.
FDA 510(k) Cleared
compliance_program